Tags : Cyclica

PharmaShots Weekly Snapshot (January 20-24, 2020)

1. Epizyme’s Tazverik (tazemetostat) Receives the US FDA’s Accelerated Approval as the First Therapy for Epithelioid Sarcoma Published: Jan 23, 2020 | Tags: Epizyme, Tazverik, tazemetostat, Receives, US, FDA, Accelerated Approval, First Therapy, Epithelioid Sarcoma 2. Evarsana Signs an Agreement with Evoke Pharma to Commercialize Gimoti in the US Published: Jan 23, 2020 | Tags: Evarsana, Signs, […]Read More

Cyclica and AUM Biosciences Collaborate to Develop Novel Cancer Therapies

Shots: Cyclica to receive up front, milestones upon completion of specific stages for Project Nexus. AUM to get right to develop & commercialize therapies resulting from Project Nexus The collaboration leverages AUM’s drug development expertise including its biomarker-driven approach with Cyclica’s AI-augmented and structure-based platform, Ligand Design and Ligand Express The companies will design molecules […]Read More

Yuhan Pharmaceutical Collaborates with Cyclica to Enhance Drug Development Utilizing

Shots: Cyclica to receive up front and milestones on completion of specific objectives. Yuhan will leverage Cyclica’s AI integrated drug discovery platform, Ligand Design and Ligand Express in two separate R&D programs Yuhan enhance its drug development efforts by utilizing AI integrated drug discovery platform across multiple therapeutic areas to develop novel therapies targeting Yuhan’s […]Read More

Merck Licenses Cyclica’s In-Silico Artificial Intelligence (AI) based Ligand Express

Shots: Merck to get rights for Cyclica’s cloud-based in-silico proteome screening AI platform, Ligand Express to screen small molecule for determining polypharmacological profiles The focus of agreement is to discover and develop clinical candidates using AI and computational biophysics Ligand Express Platform is an AI based platform, used for understanding drug’s effect with captured panoramic […]Read More